Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.

Park, Keon Young; Hefti, Hunter O; Liu, Peng; Lugo-Cintrón, Karina M; Kerr, Sheena C; Beebe, David J

Park, Keon Young; Hefti, Hunter O; Liu, Peng; Lugo-Cintrón, Karina M; Kerr, Sheena C; Beebe, David J.

Affiliation

Park KY; Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Hefti HO; Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.
Liu P; Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Lugo-Cintrón KM; Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Kerr SC; Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.
Beebe DJ; Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.

Integr Biol (Camb) ; 13(11): 259-268, 2021 12 30.

Article de En | MEDLINE | ID: mdl-34931665

Sujet(s)
Mots clés

cabozantinib; cancer immunology; microfluidics; renal cell carcinoma; tumor microenvironment

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Néphrocarcinome / Tumeurs du rein Type d'étude: Prognostic_studies Limites: Female / Humans / Male Langue: En Journal: Integr Biol (Camb) Sujet du journal: BIOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google